logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9440957 B1

PDFFull Text
Date of Patent:
Sep. 13, 2016

Filed:

Jun. 05, 2013

Compounds and compositions for modulating egfr activity

Applicants:

Gerald Lelais, San Diego, CA (US);

Robert Epple, Solana Beach, CA (US);

Thomas H. Marsilje, Iii, San Diego, CA (US);

Pierre-yves Michellys, San Marcos, CA (US);

Matthew Mcneill, San Clemente, CA (US);

Yun Long, San Diego, CA (US);

Wenshuo LU, San Diego, CA (US);

Bei Chen, San Diego, CA (US);

Badry Bursulaya, Escondido, CA (US);

Songchun Jiang, San Diego, CA (US);

Inventors:

Gerald Lelais, San Diego, CA (US);

Robert Epple, Solana Beach, CA (US);

Thomas H. Marsilje, III, San Diego, CA (US);

Pierre-Yves Michellys, San Marcos, CA (US);

Matthew McNeill, San Clemente, CA (US);

Yun Long, San Diego, CA (US);

Wenshuo Lu, San Diego, CA (US);

Bei Chen, San Diego, CA (US);

Badry Bursulaya, Escondido, CA (US);

Songchun Jiang, San Diego, CA (US);

Assignee:

Novartis AG, Basel, CH;

Attorneys:

Emily T. Wu

Genomics Institute of the Novartis Research Foundation

Primary Examiner:

Brenda Coleman

Int. Cl.
CPC ...
A61K 31/55 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 411/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); A61K 31/4184 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/551 (2006.01); A61K 31/553 (2006.01); A61K 45/06 (2006.01); C07D 401/04 (2006.01); C07D 413/04 (2006.01); C07D 471/04 (2006.01); C07D 513/04 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); A61K 31/4184 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 31/553 (2013.01); A61K 45/06 (2013.01); C07D 401/04 (2013.01); C07D 403/04 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 513/04 (2013.01);
Abstract

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.

Find Patent Forward Citations

Loading…